Vifor Pharma andAngion Biomedica Corp announced that the phase-III trial of Angion’s ANG-3777 did not demonstrate a statistically significant difference from placebo on the primary endpoint (eGFR at 12 months) in the population of deceased donor kidney transplant patients who were at risk for developing DGF.
- Read more about Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/vifor-pharma-and-angion-report-topline-results-from-phase-iii-registration-trial-of-ang-3777-in-kidney-transplant-patients-at-risk-for-delayed-graft-function
No comments:
Post a Comment